Skip to main content
Journal cover image

HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.

Publication ,  Journal Article
Nelson, CS; Huffman, T; Jenks, JA; Cisneros de la Rosa, E; Xie, G; Vandergrift, N; Pass, RF; Pollara, J; Permar, SR
Published in: Proc Natl Acad Sci U S A
June 12, 2018

Human cytomegalovirus (HCMV) is the most common congenital infection worldwide, frequently causing hearing loss and brain damage in afflicted infants. A vaccine to prevent maternal acquisition of HCMV during pregnancy is necessary to reduce the incidence of infant disease. The glycoprotein B (gB) + MF59 adjuvant subunit vaccine platform is the most successful HCMV vaccine tested to date, demonstrating ∼50% efficacy in preventing HCMV acquisition in multiple phase 2 trials. However, the mechanism of vaccine protection remains unknown. Plasma from 33 postpartum women gB/MF59 vaccinees at peak immunogenicity was tested for gB epitope specificity as well as neutralizing and nonneutralizing anti-HCMV effector functions and compared with an HCMV-seropositive cohort. gB/MF59 vaccination elicited IgG responses with gB-binding magnitude and avidity comparable to natural infection. Additionally, IgG subclass distribution was similar with predominant IgG1 and IgG3 responses induced by gB vaccination and HCMV infection. However, vaccine-elicited antibodies exhibited limited neutralization of the autologous virus, negligible neutralization of multiple heterologous strains, and limited binding responses against gB structural motifs targeted by neutralizing antibodies including AD-1, AD-2, and domain I. Vaccinees had high-magnitude IgG responses against AD-3 linear epitopes, demonstrating immunodominance against this nonneutralizing, cytosolic region. Finally, vaccine-elicited IgG robustly bound membrane-associated gB on the surface of transfected or HCMV-infected cells and mediated virion phagocytosis, although were poor mediators of NK cell activation. Altogether, these data suggest that nonneutralizing antibody functions, including virion phagocytosis, likely played a role in the observed 50% vaccine-mediated protection against HCMV acquisition.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Proc Natl Acad Sci U S A

DOI

EISSN

1091-6490

Publication Date

June 12, 2018

Volume

115

Issue

24

Start / End Page

6267 / 6272

Location

United States

Related Subject Headings

  • Young Adult
  • Viral Envelope Proteins
  • Vaccines, Subunit
  • Squalene
  • Polysorbates
  • Immunoglobulin G
  • Humans
  • Female
  • Epitopes
  • Cytomegalovirus Vaccines
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nelson, C. S., Huffman, T., Jenks, J. A., Cisneros de la Rosa, E., Xie, G., Vandergrift, N., … Permar, S. R. (2018). HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc Natl Acad Sci U S A, 115(24), 6267–6272. https://doi.org/10.1073/pnas.1800177115
Nelson, Cody S., Tori Huffman, Jennifer A. Jenks, Eduardo Cisneros de la Rosa, Guanhua Xie, Nathan Vandergrift, Robert F. Pass, Justin Pollara, and Sallie R. Permar. “HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.Proc Natl Acad Sci U S A 115, no. 24 (June 12, 2018): 6267–72. https://doi.org/10.1073/pnas.1800177115.
Nelson CS, Huffman T, Jenks JA, Cisneros de la Rosa E, Xie G, Vandergrift N, et al. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6267–72.
Nelson, Cody S., et al. “HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.Proc Natl Acad Sci U S A, vol. 115, no. 24, June 2018, pp. 6267–72. Pubmed, doi:10.1073/pnas.1800177115.
Nelson CS, Huffman T, Jenks JA, Cisneros de la Rosa E, Xie G, Vandergrift N, Pass RF, Pollara J, Permar SR. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6267–6272.
Journal cover image

Published In

Proc Natl Acad Sci U S A

DOI

EISSN

1091-6490

Publication Date

June 12, 2018

Volume

115

Issue

24

Start / End Page

6267 / 6272

Location

United States

Related Subject Headings

  • Young Adult
  • Viral Envelope Proteins
  • Vaccines, Subunit
  • Squalene
  • Polysorbates
  • Immunoglobulin G
  • Humans
  • Female
  • Epitopes
  • Cytomegalovirus Vaccines